Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Digestive System Diseases

Skin and Connective Tissue Diseases

Rare Diseases

Carcinoma

Carcinoma, Renal Cell

Gastrointestinal Stromal Tumors

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Neoplasms, Connective Tissue

Neoplasms, Connective and Soft Tissue

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Angiogenesis Inhibitors

Growth Inhibitors

When PD is being determined the patient will continue with the oral angiogenesis inhibitors for 2 more weeks. After 2 weeks, an Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI). After evaluating these scans patients in group A now stop the orale angiogenesis inhibitor.

When PD is being determined the patient will continue with the oral angiogenesis inhibitors for 2 more weeks. After 2 weeks, an Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI). After evaluating these scans patients in group B continue with angiogenesis inhibitors for 2 more weeks. After these 2 weeks(so 4 weeks after inclusion) another Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI) and a FDG-PET-scan.

usage oral angiogenesis inhibitor

stop oral angiogenesis inhibitor

C.M.L. van Herpen, Md, Phd

C.M.L van Herpen, Md, Phd

C.M.L. van Herpen, MD, Phd

The purpose of this study is to determine if and how often an unexpected fast increase of disease and complaints shows after stopping the anti-angiogenetic therapy

Until now, in trials it is common to stop therapy when progressive disease occurs; RECIST criteria are used, in which progressive disease is defined as \>20% increase of the sum of the longest diameter of the lesions, or occurence of new lesions. However, angiogenesis inhibitors have a rather cytostatic than cytotoxic effect compared to chemotherapeutics, as a result of which less frequently reduction of tumor volume is being seen.

Often in the centre of the lesion necrosis is shown. Sometimes accompanied with edema; so even tumor volume increase can be the result without real progression being the case. Recently, in our clinic, we found a number of patients, treated with oral angiogenesis inhibitors, a remarkable quickening of progressive disease and complaints after stopping this treatment. Reintroduction of the same or another type of angiogenesis inhibitor subsequently lead to a new stabilization. The causality of this phenomenon is unknown. Perhaps that the inhibitory effect of the angiogenesis is not fully exhausted at the moment that progressive disease on CT is observed. An alternative explanation is contra reaction of longterm angiogenetic inhibition through upregulation of proangiogenic factors with subsequent vascular expansion and edema. This study means to gain more insight information about the optimal treatment policy when progressive disease is found in patients treated with oral angiogenesis inhibitors. Because of the increase of patients that is being treated with these products, both in trials as in daily clinical practice, this is important to investigate.

Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors

Radboud University Medical Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors	NCT00777504	Renal Cell Carc... Gastrointestina...	usage oral angi... stop oral angio...	18 Years -	Radboud University Medical Center
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors	NCT00777504	Renal Cell Carc... Gastrointestina...	usage oral angi... stop oral angio...	18 Years -	Radboud University Medical Center
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors	NCT00777504	Renal Cell Carc... Gastrointestina...	usage oral angi... stop oral angio...	18 Years -	Radboud University Medical Center
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors	NCT00777504	Renal Cell Carc... Gastrointestina...	usage oral angi... stop oral angio...	18 Years -	Radboud University Medical Center

Spots Global Cancer Trial Database for duration of therapy